Investment analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Trevena Trading Down 4.4 %
TRVN opened at $1.30 on Wednesday. The business’s 50 day moving average is $1.67 and its 200-day moving average is $2.24. The stock has a market cap of $1.12 million, a PE ratio of -0.03 and a beta of 1.05. Trevena has a twelve month low of $1.13 and a twelve month high of $14.14.
About Trevena
Read More
- Five stocks we like better than Trevena
- Differences Between Momentum Investing and Long Term Investing
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Must-Own Stocks to Build Wealth This Decade
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.